Skip to main content

LCD L38837: Colon Capsule Endoscopy (CCE)

LCD L38837, Colon Capsule Endoscopy (CCE), is the Local Coverage Determination that Wisconsin Physicians Service Insurance Corporation applies to claims from 48 states (AK, AL, AR, AZ, CA, CO, CT, DE and others), effective 2025-05-29 and first in force 2021-03-28. The policy text runs 537 words, and its billing and coding article A58471 lists 6 ICD-10-CM codes that support medical necessity for 1 procedure code. 6 other contractor versions share this title, so the criteria depend on where the service is furnished. Counting every linked billing and coding article, this one lists 6 covered ICD-10-CM codes: the same total as L38571 (Wellpoint Federal, 6 codes, revised 2026-04-01) and the same total as L38755 (Palmetto GBA, 6 codes, revised 2021-04-12).

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Contractor
Wisconsin Physicians Service Insurance Corporation
States and territories
48
AK AL AR AZ CA CO CT DE FL GA HI IA ID IL IN KS KY LA MA MD ME MI MO MS MT NC ND NE NH NJ NM NV OH OK OR PA RI SC SD TN TX UT VA VT WA WI WV WY
Revision effective
2025-05-29
Original effective
2021-03-28
Policy text
537 words
Covered ICD-10 codes (articles)
6

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L38837
ContractContractorTypeStates
05101Wisconsin Physicians Service Insurance CorporationMAC - Part AIA
05201Wisconsin Physicians Service Insurance CorporationMAC - Part AKS
05301Wisconsin Physicians Service Insurance CorporationMAC - Part AMO
05401Wisconsin Physicians Service Insurance CorporationMAC - Part ANE
05102Wisconsin Physicians Service Insurance CorporationMAC - Part BIA
05202Wisconsin Physicians Service Insurance CorporationMAC - Part BKS
05302Wisconsin Physicians Service Insurance CorporationMAC - Part BMO
05402Wisconsin Physicians Service Insurance CorporationMAC - Part BNE
08101Wisconsin Physicians Service Insurance CorporationMAC - Part AIN
08102Wisconsin Physicians Service Insurance CorporationMAC - Part BIN
08201Wisconsin Physicians Service Insurance CorporationMAC - Part AMI
08202Wisconsin Physicians Service Insurance CorporationMAC - Part BMI
05901Wisconsin Physicians Service Insurance CorporationMAC - Part AAK AL AR AZ CA CO CT DE FL GA HI IA ID IL IN KS KY LA MA MD ME MI MO MS MT NC ND NE NH NJ NM NV OH OK OR PA RI SC SD TN TX UT VA VT WA WI WV WY

Billing and coding articles A56902 and A58471: diagnoses and procedure codes

Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A56902 (Billing and Coding: Category III Codes), Billing and Coding A58471 (Billing and Coding: Colon Capsule Endoscopy (CCE)) carry the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.

Coverage is only half of the claim edit: when two of the listed procedure codes are billed on the same date, test the pair against the NCCI edits before relying on both being paid.

A56902: Billing and Coding: Category III Codes (Billing and Coding, effective 2026-01-01)

Covered ICD-10-CM codes
0
0 groups
Non-covered ICD-10-CM codes
0
Procedure codes listed
13
Full article
cms.gov record

Procedure codes: 0075T, 0076T, 0184T, 0308T, 0395T, 0525T, 0526T, 0527T, 0528T, 0529T, 0530T, 0531T, 0532T.

A58471: Billing and Coding: Colon Capsule Endoscopy (CCE) (Billing and Coding, effective 2023-02-23)

Covered ICD-10-CM codes
6
1 group
Non-covered ICD-10-CM codes
0
Procedure codes listed
1
Full article
cms.gov record
First 6 covered ICD-10-CM codes in A58471
ICD-10-CMDescription (FY2027)
K63.5Polyp of colon
K92.1Melena
K92.2Gastrointestinal hemorrhage, unspecified
R19.5Other fecal abnormalities
Z53.09Procedure and treatment not carried out because of other contraindication
Z53.8Procedure and treatment not carried out for other reasons

Procedure codes: 91113.

Coverage indications, limitations and medical necessity

Compliance with the provisions in this policy may be monitored and addressed through post payment data analysis and subsequent medical review audits.

History/Background and/or General Information

Colon capsule endoscopy (CCE) is a noninvasive procedure that does not require air inflation or sedation and allows for minimally invasive and painless colonic evaluation. CCE utilizes a tiny wireless camera that takes pictures of the gastrointestinal tract. The wireless camera is housed inside a vitamin-size capsule that is swallowed with water. As the capsule travels through the digestive tract, the camera takes pictures that are transmitted to a recorder worn by the patient. The images are then transmitted to a computer with special software where the images are strung together to create a video. The provider reviews the video to look for any abnormalities within the gastrointestinal tract.

Definitions (U.S. Multisociety Taskforce)

Cancer Screening strategies refer to those measures taken to diagnose cancerous and pre-cancerous lesions in asymptomatic people with no previous history of such. 1

Cancer Diagnostic strategies refer to the measures taken to investigate persons with symptoms suspicious for malignancy or as a result of positive screening tests. 1

Cancer Surveillance refers to the interval utilization of diagnostic strategies in people with previously detected cancerous or pre-cancerous lesions. 1

Covered Indications

For diagnostic and/or surveillance purposes, Colon capsule endoscopy (CCE) is medically necessary when EITHER of the following criteria are met:

• Primary procedure in patients with major risks for Optical Colonoscopy (OC) or moderate sedation as indicated from an evaluation of the patient by a board certified or board eligible gastroenterologist, a surgeon trained in endoscopy, or a physician with equivalent endoscopic training and EITHER of the following criteria are met: 2

• Fecal Occult Blood Test (FOBT) positive (guaiac or immunochemical) OR

• Multitarget Stool DNA (sDNA) Test positive OR

• Other evidence of lower GI bleeding in hemodynamically stable patients

• Secondary procedure:

• For the detection or surveillance of colon polyp(s) if the diagnostic OC was incomplete OR

• When an incomplete diagnostic OC was performed for either:

• Fecal Occult Blood Test (FOBT) positive (guaiac or immunochemical) OR

• Multitarget Stool DNA (sDNA) Test positive OR

• Other evidence of lower GI bleeding in hemodynamically stable patients

Limitations

The following are considered not medically reasonable and necessary:

• Patients with known or suspected gastrointestinal obstruction, stricture, or fistula.

• Patients with a cardiac pacemaker or another implanted electro-medical device.

• Patients with swallowing disorder(s).

• Patients with a known contraindication or allergy to any medication or preparation agent used before or during the procedure.

• When performed in conjunction with CT Colonography (CTC).

• CCE is not a Medicare Benefit for colorectal cancer screening, regardless of family history or other risk factors for the development of colonic disease. Please refer to NCD 210.3 for colorectal cancer screening coverage.

Notice: Services performed for any given diagnosis must meet all the indications and limitations stated in this policy, the general requirements for medical necessity as stated in CMS payment policy manuals, any and all existing CMS national coverage determinations, and all Medicare payment rules.

The redetermination process may be utilized for consideration of services performed outside of the reasonable and necessary requirements in this LCD.

Summary of evidence (opening)

Clinical Literature

The first-generation device had low sensitivity and specificity for polyps in the colon; however, a second-generation device received FDA clearance in January 2014 and expanded use in January 2016. 3,4 The improved design is slightly bigger with 2 cameras and an increased angle of view, allowing nearly 360-degree coverage of the colon. The capsule battery lasts 10 hours with a slower frame rate. Improvements in software allow estimation of polyp size and improved mucosal surface evaluation. Unless indicated, a reference to CCE is specific to the second-generation device. Both FDA indications are specific to colon polyp detection, but whereas the original restricted to use as a secondary procedure after failed OC, the expanded indication included use as a primary procedure in patients at major risk for colonoscopy or moderate sedation, and with evidence of lower GI bleeding.

The pivotal trial that led to FDA clearance was a prospective blinded study of 884 asymptomatic patients classified as average colorectal cancer (CRC) risk. 5 Technical failures (short transit time plus poor preparation) occurred in 9% of patients. The authors conclude based on polyp detection sensitivity and specificity data that: “capsule performance seems adequate for patients who cannot undergo colonoscopy or who had incomplete colonoscopies.”

Two studies comparing CCE to CTC demonstrated at least non-inferiority in terms of sensitivity and specificity. 6,7 One found improved sensitivity and specificity for CCE, but both studies had methodological flaws with low-quality evidence. The advantages of CTC include the ability to use when obstruction or stricture is a concern and to obtain visualization of other abdominal structures. Advantages to CCE are the lack of radiation exposure and direct visualization of colorectal mucosa. Patient preference and availability of the technology also may play a role in test selection.

The contractor cites 23 sources in the bibliography; the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2021-03-28
Current revision effective
2025-05-29
Last reviewed by the contractor
2025-04-15
MCD version
7

The contractor lists one National Coverage Determination as related: NCD 210.3 Colorectal Cancer Screening Tests. Where an NCD speaks, it controls; the LCD can only address what the NCD leaves open.

Other related documents: A58624 (Response to Comments).

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the Wisconsin Physicians Service Insurance Corporation hub lists every other active policy from the same contractor.

The same policy title at other contractors

Contractors often adopt each other's policies and then revise them separately, so the criteria and the diagnosis lists drift apart. The topic comparison lines up every version.

For teams evaluating QuickIntell software

Where QuickIntell fits with this policy

If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does LCD L38837 cover?

Colon capsule endoscopy (CCE) is a noninvasive procedure that does not require air inflation or sedation and allows for minimally invasive and painless colonic evaluation. CCE utilizes a tiny wireless camera that takes pictures of the gastrointestinal tract. The wireless camera is housed inside a vitamin-size capsule that is swallowed with water. As the capsule travels through the digestive tract, the camera takes… The full 537-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.

Which states does LCD L38837 apply to?

Wisconsin Physicians Service Insurance Corporation applies it to Medicare claims in 48 states: AK, AL, AR, AZ, CA, CO, CT, DE, FL, GA, HI, IA, ID, IL, IN, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NC, ND, NE, NH, NJ, NM, NV, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VA, VT, WA, WI, WV, WY. It binds only that contractor; 6 other contractor versions of this title govern other jurisdictions, and elsewhere the same service is judged under the local contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L38837?

The companion billing and coding article A58471 lists 6 ICD-10-CM codes in 1 group that support medical necessity; the first 6 appear on this page, where the complete list opens by group with the contractor's group instructions.

How do I appeal a denial under LCD L38837?

A denial under LCD L38837 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A58471's 6 covered diagnosis codes, then file a redetermination with Wisconsin Physicians Service Insurance Corporation within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.